Private equity's big-money deals are back: 5 trends for ASCs and physicians

The billion-dollar deal is back in healthcare. After two years of elevated interest rates and regulatory uncertainty forced private equity firms to sit on their hands, 2025 delivered $191 billion in healthcare PE investment according to VMG Health—and the capital deployment strategy has fundamentally shifted. For ambulatory surgery centers and physician practice platforms, this isn't just a return to 2021's dealmaking frenzy. It's a recalibration toward longer hold periods, operational intensity, and a regulatory landscape where 35 states now impose transaction review requirements that didn't exist three years ago.

The thesis: PE's ambulatory surgical center (ASC) playbook is evolving from roll-up arbitrage to genuine operational transformation, and firms that can't deliver margin improvement through technology integration and clinical excellence will find themselves trapped in seven-year holds with no exit.

I. Deal Size and Structure: The $1 Billion Floor Returns

VMG Health's 2025 data shows overall transaction volume grew modestly year-over-year, but average deal size surged. Transactions exceeding $1 billion—largely absent in 2023 and 2024—reappeared as sponsor-to-sponsor sales nearly doubled from prior-year levels. This signals two critical shifts: confidence in exit valuations has returned, and secondary buyout markets are liquid again.

For ASC platforms, this matters because it validates the thesis that scaled ambulatory networks command premium multiples. Single-site ASCs historically trade at 6-8x EBITDA; platforms with 20+ centers and payor contracting leverage now clear 12-14x in competitive processes. The spread creates powerful incentives for continued consolidation, particularly in high-margin specialties where case volumes justify hub-and-spoke expansion models.

The implication: if you're a PE-backed ASC platform formed between 2019-2021, your sponsor is actively modeling secondary sale scenarios. Operational underperformance that made sense during the "hold and pray" period of 2023-2024 is now a barrier to exit at target IRR.

II. Specialty Rotation: Beyond Ophthalmology and Dentistry

Private equity's historic focus on ophthalmology, dentistry, and dermatology—high-volume, procedural, insurance-insulated specialties—is expanding into higher-acuity terrain. VMG Health reports significant 2025 investment in cardiology and orthopedics, alongside behavioral health, medical aesthetics, and healthcare IT.

For ASCs, cardiology represents the most significant frontier. Interventional cardiology procedures increasingly migrate to outpatient settings as device technology improves and CMS payment policies favor site-neutral care. Structural heart programs—particularly transcatheter aortic valve replacement (TAVR) and left atrial appendage closure—are moving into ASCs at academic medical centers and large cardiology groups. PE firms see margin opportunity: hospital outpatient departments charge facility fees 2.5-3.0x higher than ASC rates for identical procedures, creating powerful incentives for commercial payors to steer volume.

Orthopedics follows similar logic. Total joint replacement migrated to ASCs over the past decade; spine procedures—particularly lumbar fusion and disc replacement—are next. The clinical barrier has fallen: 30-day complication rates for outpatient spine surgery match inpatient outcomes for appropriate patient selection, per data published in The Spine Journal and cited by the Ambulatory Surgery Center Association.

III. Technology as Valuation Multiplier

"Tech-enabled" transformed from marketing language to genuine pricing lever in 2025. VMG Health pegs healthcare IT investment at $32 billion, but the operational impact extends beyond pure software companies. ASC platforms integrating AI-driven scheduling optimization, automated prior authorization, and predictive staffing models command valuation premiums of 150-200 basis points over peers with legacy systems.

The mechanism is straightforward: labor represents 55-60% of ASC operating expense, per Medical Group Management Association benchmarks. AI scheduling tools that increase OR utilization from 72% (industry median) to 84% drop 8-10 percentage points straight to EBITDA margin. At a 12x exit multiple, that's $960,000 in enterprise value per percentage point of margin improvement for a $10 million EBITDA platform.

Investors specifically hunt for platforms using machine learning for case duration prediction, automated supply chain management tied to surgeon preference cards, and remote patient monitoring that reduces day-of-surgery cancellations. These aren't speculative investments—the ROI case closes in 14-18 months based on reduced staffing costs and increased case throughput.

IV. Extended Holds and the Operational Imperative

Hold periods now routinely exceed five years, fundamentally changing investment strategy. The 2019-2021 vintage of ASC deals—underwritten at 3.5-4.5 year hold assumptions—is aging into year six and seven. VMG Health confirms firms prioritized operational improvement over new M&A through most of 2024 and early 2025, though momentum picked up in Q4 2025.

This shift elevates operational expertise from nice-to-have to existential. Funds can no longer rely on multiple expansion and bolt-on acquisitions to hit return targets. Margin improvement must come from clinical efficiency, payor rate negotiation, and supply chain optimization.

The clearest evidence: management consulting spend at PE-backed ASC platforms increased 140% from 2022 to 2025, according to industry data from Becker's ASC Review. Firms are hiring former hospital COOs, bringing in Lean Six Sigma practitioners, and building internal corporate development teams focused on operational integration rather than deal origination.

For physicians partnering with PE-backed platforms, this means intensified scrutiny of clinical productivity metrics, case scheduling patterns, and supply utilization. The "hands-off" platform model that characterized early ASC roll-ups is dead. Expect quarterly surgeon scorecards, mandatory participation in group purchasing organizations, and pressure to standardize implant selection.

V. Regulatory Fragmentation Creates Execution Risk

The Hart-Scott-Rodino Act filing threshold increased to $126.4 million for 2025, theoretically reducing federal antitrust review for smaller deals. But state-level regulation accelerated dramatically: 35+ states now require transaction notifications, and several adopted PE-specific review standards.

Massachusetts, California, New York, and Oregon lead with laws requiring 90-180 day advance notice for healthcare transactions, with authority to block deals deemed harmful to access or competition. Minnesota and Washington enacted 2025 legislation specifically targeting private equity healthcare acquisitions, requiring ongoing operational reporting post-close.

For ASC investors, this fragments deal execution timelines and introduces regulatory rejection risk that didn't exist in prior cycles. A 50-center ASC platform operating across 12 states may face notification requirements in eight jurisdictions, each with different materiality thresholds, review standards, and political dynamics.

The "Friendly PC" model—where PE firms purchase assets while physicians retain the professional corporation—faces parallel pressure. The Federal Trade Commission's 2024 policy statement on corporate practice of medicine enforcement and ongoing litigation in Texas and California create uncertainty around structure that historically insulated PE investments from licensing restrictions.

The Bottom Line: Operationalize or Exit at Discount

Private equity's return to healthcare in 2025 reflects genuine conviction that ambulatory surgery economics work at scale—but only for platforms that execute operationally. The firms winning exits at 14-16x EBITDA demonstrate measurable margin improvement through technology integration, clinical standardization, and payor contracting leverage.

For institutional investors evaluating ASC platform opportunities, three diligence questions matter: First, can management articulate specific operational initiatives with quantified EBITDA impact beyond "we'll add more centers"? Second, does the platform's technology stack actually drive efficiency, or is it legacy practice management software with an API? Third, how does the regulatory footprint across states affect both deal timing and ongoing compliance cost?

The ASC investment opportunity remains compelling—case migration from hospital outpatient departments continues, CMS rate increases favor ambulatory settings, and clinical outcomes data supports expansion into higher-acuity procedures. But the era of financial engineering-driven returns is over. Winning the next cycle requires operational sophistication that most healthcare PE firms are still building.

---

1. VMG Health, "Healthcare Services M&A Report 2025," VMG Health, 2025.

2. Becker's ASC Review, "Private equity's big-money deals are back: 5 trends for ASCs and physicians," March 2025.

3. Medical Group Management Association, "Cost and Revenue Survey 2024," MGMA, 2024.

4. Ambulatory Surgery Center Association, clinical outcomes data on outpatient spine procedures, 2024-2025.

5. Federal Trade Commission, "Policy Statement on Corporate Practice of Medicine," FTC, 2024.